Immune Checkpoint Inhibitor Therapy Achieved Complete Response for Drug-Sensitive EGFR/ALK Mutation-Negative Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma with High Tumor Mutation Burden: A Case Report

References

• Fasano M, Della Corte CM, Papaccio F, et al. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10(8):1133–1141. doi:10.1097/JTO.000000000000058926039012
   PubMed Web of Science ®Google Scholar
• Eichhorn F, Dienemann H, Muley T, et al. Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 2015;99(3):983–989. doi:10.1016/j.athoracsur.2014.10.01525596870
   PubMed Web of Science ®Google Scholar
• Rossi G, Cavazza A, Marchioni A, et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005;23(34):8774–8785. doi:10.1200/JCO.2005.02.823316314638
   PubMed Web of Science ®Google Scholar
• Saji H, Tsuboi M, Matsubayashi J, et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs. 2010;21(1):89–93. doi:10.1097/CAD.0b013e328330fd7919770636
   PubMed Web of Science ®Google Scholar
• Filosso PL, Guerrera F, Evangelista A, et al. Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma: results from the European society for thoracic surgeons lung neuroendocrine tumours retrospective database. Eur J Cardiothorac Surg. 2017;52:339–345. doi:10.1093/ejcts/ezx10128459956
   PubMed Web of Science ®Google Scholar
• Zhang JT, Li Y, Yan LX, et al. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: a multi-center retrospective study. Lung Cancer. 2020;139:118–123. doi:10.1016/j.lungcan.2019.11.00431775086
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc323922437870
   PubMed Web of Science ®Google Scholar
• Su MY, Fisher DE. Immunotherapy in the precision medicine era: melanoma and beyond. PLoS Med. 2016;13(12):e1002196. doi:10.1371/journal.pmed.100219627959922
   PubMed Web of Science ®Google Scholar
• Cao L, Li ZW, Wang M, et al. Clinicopathological characteristics, treatment and survival of pulmonary large cell neuroendocrine carcinoma: a SEER population-based study. PeerJ. 2019;7:e6539. doi:10.7717/peerj.653930944773
   PubMed Web of Science ®Google Scholar
• Xu F, Chen K, Lu C, et al. Large cell neuroendocrine carcinoma shares similarity with small cell carcinoma on the basis of clinical and pathological features. Transl Oncol. 2019;12(4):646–655. doi:10.1016/j.tranon.2019.01.00430818166
   PubMed Web of Science ®Google Scholar
• Iyoda A, Hiroshima K, Moriya Y, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006;82(5):1802–1807. doi:10.1016/j.athoracsur.2006.05.10917062251
   PubMed Web of Science ®Google Scholar
• Weber MM, Fottner C. Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia. Oncol Res Treat. 2018;41(5):306–312. doi:10.1159/00048899629742518
   PubMed Web of Science ®Google Scholar
• Levra MG, Mazieres J, Valette CA, et al. P1.07-012 efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer: results from a french retrospective cohort. J Thorac Oncol. 2017;12(1):S702–S703. doi:10.1016/j.jtho.2016.11.923
   Web of Science ®Google Scholar
• Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050. doi:10.1183/13993003.00050-201728798088
   PubMed Web of Science ®Google Scholar
• Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71–74. doi:10.1016/j.lungcan.2017.11.01929290265
   PubMed Web of Science ®Google Scholar
• Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer. 2018;125:150–156. doi:10.1016/j.lungcan.2018.09.01530429014
   PubMed Web of Science ®Google Scholar
• Sugano T, Seike M, Saito Y, et al. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer. 2020;11(4):1052–1060. doi:10.1111/1759-7714.1336432096610
   PubMed Web of Science ®Google Scholar
• Baba T, Sakai F, Kato T, et al. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. Future Oncol. 2019;15(16):1911–1920. doi:10.2217/fon-2019-010231020849
   PubMed Web of Science ®Google Scholar
• Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018;154(6):1416–1423. doi:10.1016/j.chest.2018.08.104830189190
   PubMed Web of Science ®Google Scholar
• Galuppini F, Dal Pozzo CA, Deckert J, et al. Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell Int. 2019;19(1):202. doi:10.1186/s12935-019-0929-431384177
   PubMed Web of Science ®Google Scholar
• Cao D, Xu H, Xu X, et al. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. OncoImmunology. 2019;8(9):1–12. doi:10.1080/2162402X.2019.1629258
   Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-228420421
   PubMed Web of Science ®Google Scholar
• Wang VE, Urisman A, Albacker L, et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017;5(1):75. doi:10.1186/s40425-017-0281-y28923100
   PubMedGoogle Scholar
• Gandara DR, Paul SM, Marcin K, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–1448. doi:10.1038/s41591-018-0134-330082870
   PubMed Web of Science ®Google Scholar